Hydrogen sulfide mitigates hyperglycemic remodeling via liver kinase B1-adenosine monophosphate-activated protein kinase signaling

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 12, 2014, Pages 2816-2826

  Kundu, Sourav ^a   Pushpakumar, Sathnur ^a   Khundmiri, Syed J ^a   Sen, Utpal ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Autophagy; Diabetes; Extracellular matrix; LKB1 STRAD MO25; Sodium hydrogen sulfide

Indexed keywords

AUTOPHAGY PROTEIN 3; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; CALCIUM BINDING PROTEIN; CALCIUM BINDING PROTEIN 39; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; ENZYME; GALECTIN 3; GLUCOSE; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER KINASE B1; SMALL INTERFERING RNA; STE 20 RELATED ADAPTOR PROTEIN ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHAGY; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENE SILENCING; HYPERGLYCEMIA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84907459409     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.08.005     Document Type: Article

References (55)

1. Kimura H. The physiological role of hydrogen sulfide and beyond. Nitric Oxide 2014, [Epub ahead of print]. 10.1016/j.niox.2014.01.002.
2. Kundu S., Pushpakumar S.B., Tyagi A., Coley D., Sen U. Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9. Am. J. Physiol. Endocrinol. Metab. 2013, 304:E1365-E1378.
3. Yamamoto J., Sato W., Kosugi T., Yamamoto T., Kimura T., Taniguchi S., Kojima H., Maruyama S., Imai E., Matsuo S., Yuzawa Y., Niki I. Distribution of hydrogen sulfide (H(2)S)-producing enzymes and the roles of the H(2)S donor sodium hydrosulfide in diabetic nephropathy. Clin. Exp. Nephrol. 2013, 17:32-40.
4. Hardie D.G. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond.) 2008, 32(Suppl. 4):S7-S12.
5. Alessi D.R., Sakamoto K., Bayascas J.R. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
6. Lee M.J., Feliers D., Mariappan M.M., Sataranatarajan K., Mahimainathan L., Musi N., Foretz M., Viollet B., Weinberg J.M., Choudhury G.G., Kasinath B.S. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am. J. Physiol. Ren. Physiol. 2007, 292:F617-F627.
7. Lee H.J., Mariappan M.M., Feliers D., Cavaglieri R.C., Sataranatarajan K., Abboud H.E., Choudhury G.G., Kasinath B.S. Hydrogen sulfide inhibits high glucose-induced matrix protein synthesis by activating AMP-activated protein kinase in renal epithelial cells. J. Biol. Chem. 2012, 287:4451-4461.
8. Eid A.A., Ford B.M., Block K., Kasinath B.S., Gorin Y., Ghosh-Choudhury G., Barnes J.L., Abboud H.E. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J. Biol. Chem. 2010, 285:37503-37512.
9. Dugan L.L., You Y.H., Ali S.S., Diamond-Stanic M., Miyamoto S., Decleves A.E., Andreyev A., Quach T., Ly S., Shekhtman G., Nguyen W., Chepetan A., Le T.P., Wang L., Xu M., Paik K.P., Fogo A., Viollet B., Murphy A., Brosius F., Naviaux R.K., Sharma K. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J. Clin. Invest. 2013, 123:4888-4899.
10. Satriano J., Sharma K. Autophagy and metabolic changes in obesity-related chronic kidney disease. Nephrol. Dial. Transplant. 2013, 28(Suppl. 4):iv29-iv36.
11. Meijer A.J., Codogno P. AMP-activated protein kinase and autophagy. Autophagy 2007, 3:238-240.
12. Meley D., Bauvy C., Houben-Weerts J.H., Dubbelhuis P.F., Helmond M.T., Codogno P., Meijer A.J. AMP-activated protein kinase and the regulation of autophagic proteolysis. J. Biol. Chem. 2006, 281:34870-34879.
13. Fang L., Zhou Y., Cao H., Wen P., Jiang L., He W., Dai C., Yang J. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One 2013, 8:e60546.
14. Yamahara K., Kume S., Koya D., Tanaka Y., Morita Y., Chin-Kanasaki M., Araki H., Isshiki K., Araki S., Haneda M., Matsusaka T., Kashiwagi A., Maegawa H., Uzu T. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J. Am. Soc. Nephrol. 2013, 24:1769-1781.
15. Lee C.H., Inoki K., Guan K.L. mTOR pathway as a target in tissue hypertrophy. Annu. Rev. Pharmacol. Toxicol. 2007, 47:443-467.
16. Yang Y., Wang J., Qin L., Shou Z., Zhao J., Wang H., Chen Y., Chen J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol. 2007, 27:495-502.
17. Sakaguchi M., Isono M., Isshiki K., Sugimoto T., Koya D., Kashiwagi A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem. Biophys. Res. Commun. 2006, 340:296-301.
18. Fryer L.G., Parbu-Patel A., Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 2002, 277:25226-25232.
19. Kim J., Shon E., Kim C.S., Kim J.S. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp. Diabetes Res. 2012, 2012:210821.
20. Pushpakumar S.B., Kundu S., Metreveli N., Tyagi S.C., Sen U. Matrix metalloproteinase inhibition mitigates renovascular remodeling in salt-sensitive hypertension. Physiol. Rep. 2013, 1:e00063.
21. Orlova K.A., Parker W.E., Heuer G.G., Tsai V., Yoon J., Baybis M., Fenning R.S., Strauss K., Crino P.B. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J. Clin. Invest. 2010, 120:1591-1602.
22. Godlewski J., Nowicki M.O., Bronisz A., Nuovo G., Palatini J., De Lay M., Van Brocklyn J., Ostrowski M.C., Chiocca E.A., Lawler S.E. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 2010, 37:620-632.
23. Xia M., Chen L., Muh R.W., Li P.L., Li N. Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J. Pharmacol. Exp. Ther. 2009, 329:1056-1062.
24. Xue R., Hao D.D., Sun J.P., Li W.W., Zhao M.M., Li X.H., Chen Y., Zhu J.H., Ding Y.J., Liu J., Zhu Y.C. Hydrogen sulfide treatment promotes glucose uptake by increasing insulin receptor sensitivity and ameliorates kidney lesions in type 2 diabetes. Antioxid. Redox Signal. 2013, 19:5-23.
25. Yuan P., Xue H., Zhou L., Qu L., Li C., Wang Z., Ni J., Yu C., Yao T., Huang Y., Wang R., Lu L. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. Nephrol. Dial. Transplant. 2011, 26:2119-2126.
26. Wen Y.D., Wang H., Kho S.H., Rinkiko S., Sheng X., Shen H.M., Zhu Y.Z. Hydrogen sulfide protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and oxidative stress. PLoS One 2013, 8:e53147.
27. Jung K.J., Jang H.S., Kim J.I., Han S.J., Park J.W., Park K.M. Involvement of hydrogen sulfide and homocysteine transsulfuration pathway in the progression of kidney fibrosis after ureteral obstruction. Biochim. Biophys. Acta 2013, 1832:1989-1997.
28. Chen P.H., Fu Y.S., Wang Y.M., Yang K.H., Wang D.L., Huang B. Hydrogen sulfide increases nitric oxide production and subsequent s-nitrosylation in endothelial cells. Sci. World J. 2014, 2014:480387.
29. King A.L., Polhemus D.J., Bhushan S., Otsuka H., Kondo K., Nicholson C.K., Bradley J.M., Islam K.N., Calvert J.W., Tao Y.X., Dugas T.R., Kelley E.E., Elrod J.W., Huang P.L., Wang R., Lefer D.J. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:3182-3187.
30. Zhao W., Zhang J., Lu Y., Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001, 20:6008-6016.
31. Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J. 2002, 16:1792-1798.
32. Polhemus D.J., Lefer D.J. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ. Res. 2014, 114:730-737.
33. Zhang B.B., Zhou G., Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009, 9:407-416.
34. Decleves A.E., Mathew A.V., Cunard R., Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol. 2011, 22:1846-1855.
35. Zhou X., Cao Y., Ao G., Hu L., Liu H., Wu J., Wang X., Jin M., Zheng S., Zhen X., Alkayed N.J., Jia J., Cheng J. CaMKKbeta-dependent activation of AMP-activated protein kinase is critical to suppressive effects of hydrogen sulfide on neuroinflammation. Antioxid. Redox Signal. 2014 Mar 13, [Epub ahead of print].
36. Manna P., Jain S.K. L-cysteine and hydrogen sulfide increase PIP3 and AMPK/PPARgamma expression and decrease ROS and vascular inflammation markers in high glucose treated human U937 monocytes. J. Cell. Biochem. 2013, 114:2334-2345.
37. Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., Alessi D.R., Clevers H.C. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 2003, 22:3062-3072.
38. Boudeau J., Scott J.W., Resta N., Deak M., Kieloch A., Komander D., Hardie D.G., Prescott A.R., van Aalten D.M., Alessi D.R. Analysis of the LKB1-STRAD-MO25 complex. J. Cell Sci. 2004, 117:6365-6375.
39. Viollet B., Foretz M., Guigas B., Horman S., Dentin R., Bertrand L., Hue L., Andreelli F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol. 2006, 574:41-53.
40. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
41. Mizushima N. Physiological functions of autophagy. Curr. Top. Microbiol. Immunol. 2009, 335:71-84.
42. Glick D., Barth S., Macleod K.F. Autophagy: cellular and molecular mechanisms. J. Pathol. 2010, 221:3-12.
43. Kume S., Thomas M.C., Koya D. Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 2012, 61:23-29.
44. Park I.S., Kiyomoto H., Abboud S.L., Abboud H.E. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997, 46:473-480.
45. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
46. Chen J.K., Chen J., Neilson E.G., Harris R.C. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J. Am. Soc. Nephrol. 2005, 16:1384-1391.
47. Herbert T.P., Kilhams G.R., Batty I.H., Proud C.G. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells. J. Biol. Chem. 2000, 275:11249-11256.
48. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 2004, 279:32771-32779.
49. Lieberthal W., Levine J.S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 2009, 20:2493-2502.
50. Satirapoj B., Wang Y., Chamberlin M.P., Dai T., Lapage J., Phillips L., Nast C.C., Adler S.G. Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol. Dial. Transplant. 2012, 27:2702-2711.
51. Kikuchi Y., Kobayashi S., Hemmi N., Ikee R., Hyodo N., Saigusa T., Namikoshi T., Yamada M., Suzuki S., Miura S. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol. Dial. Transplant. 2004, 19:602-607.
52. Xie Z., Dong Y., Scholz R., Neumann D., Zou M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008, 117:952-962.
53. Stipanuk M.H., Beck P.W. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem. J. 1982, 206:267-277.
54. Lu M., Liu Y.H., Goh H.S., Wang J.J., Yong Q.C., Wang R., Bian J.S. Hydrogen sulfide inhibits plasma renin activity. J. Am. Soc. Nephrol. 2010, 21:993-1002.
55. Lim C.T., Lolli F., Thomas J.D., Kola B., Korbonits M. Measurement of AMP-activated protein kinase activity and expression in response to ghrelin. Methods Enzymol. 2012, 514:271-287.